GOTTSCHALK ADRIAN 4

What Happened

• Adrian Gottschalk, CEO of Foghorn Therapeutics (FHTX), was granted a derivative equity award on 2026-02-05 covering 1,075,000 shares with an exercise/strike price of $5.23 per share. The report lists the aggregate grant value as $5,622,250. The filing classifies the transaction as an award/grant (code A).

Key Details

• Transaction date: 2026-02-05; filing date: 2026-02-06 (timely).
• Instrument: Derivative equity award (option) for 1,075,000 shares at $5.23 per share — total notional value shown $5,622,250.
• Vesting: The option vests 25% on February 5, 2027, then 6.25% of the underlying shares on the first day of each calendar quarter thereafter (footnote F1).
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax withholding, or late-filing flag noted in the provided data.

Context

• This was a compensation grant (an option award) rather than an open-market purchase or sale. The award vests over time, so it does not represent immediate stock purchases or sales.
• As with most option grants, the value is potential and depends on future stock price performance; it does not guarantee realized gain unless and until options are exercised and any shares sold.